164 related articles for article (PubMed ID: 37043985)
1. Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk.
Hu WS; Lin CL
J Diabetes Complications; 2023 May; 37(5):108468. PubMed ID: 37043985
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
3. Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.
Su YC; Shao SC; Lai EC; Lee CN; Hung MJ; Lai CC; Hsu SM; Hung JH
Diabetes Obes Metab; 2021 Sep; 23(9):2067-2076. PubMed ID: 34047442
[TBL] [Abstract][Full Text] [Related]
4. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
5. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database.
Fawzy AM; Rivera-Caravaca JM; Underhill P; Fauchier L; Lip GYH
Diabetes Obes Metab; 2023 Feb; 25(2):602-610. PubMed ID: 36054168
[TBL] [Abstract][Full Text] [Related]
6. Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan.
Shao SC; Su YC; Lai EC; Chang KC; Lee CN; Hung MJ; Lai CC; Huang FC; Hung JH
Diabetes Metab; 2022 Jan; 48(1):101318. PubMed ID: 35017100
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
[TBL] [Abstract][Full Text] [Related]
8. Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation.
Hu WS; Lin CL
Acta Diabetol; 2023 Jul; 60(7):981-987. PubMed ID: 37083962
[TBL] [Abstract][Full Text] [Related]
9. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
[TBL] [Abstract][Full Text] [Related]
10. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.
Su YC; Hung JH; Chang KC; Sun CC; Huang YH; Lee CN; Hung MJ; Lai CC; Shao SC; Lai EC
JAMA Netw Open; 2022 Sep; 5(9):e2232584. PubMed ID: 36136333
[TBL] [Abstract][Full Text] [Related]
12. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.
Siao WZ; Lin TK; Huang JY; Tsai CF; Jong GP
Diab Vasc Dis Res; 2022; 19(3):14791641221098168. PubMed ID: 35549730
[TBL] [Abstract][Full Text] [Related]
13. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
Yu OHY; Dell'Aniello S; Shah BR; Brunetti VC; Daigle JM; Fralick M; Douros A; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ronksley PE; Filion KB; Ernst P; Lix LM;
Diabetes Care; 2020 Oct; 43(10):2444-2452. PubMed ID: 32759360
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database.
Subramanian A; Gokhale K; Sainsbury C; Nirantharakumar K; Toulis KA
Diabetes Obes Metab; 2023 Jan; 25(1):156-165. PubMed ID: 36056476
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Fralick M; Chen SK; Patorno E; Kim SC
Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
[TBL] [Abstract][Full Text] [Related]
18. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
Cowan A; Jeyakumar N; Kang Y; Dixon SN; Garg AX; Naylor K; Weir MA; Clemens KK
Clin J Am Soc Nephrol; 2022 Jun; 17(6):835-842. PubMed ID: 35618342
[TBL] [Abstract][Full Text] [Related]
19. The lower incidence of endometrial cancer after sodium-glucose cotransporter 2 inhibitors administration in type 2 diabetes mellitus population: a nationwide cohort study.
Yang PJ; Wang PH; Huang JY; Lee CY; Lin CW; Lee CY; Yang SF
Int J Med Sci; 2024; 21(8):1408-1413. PubMed ID: 38903923
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA
Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
